Zafgen receives $20.0M in Venture Round funding
Actavis, Forest Labs get second FTC request for merger info
Teva Pharmaceuticals will be releasing its generic version of Celebrex by year's end
Visit our sites for b2b sales and banking employees:
cafeb2bsales.com
cafebanking.com
Submit an article to cafepharma's CP Wire. Click here to find out more.
| Company | Average | Last 24h |
Increase |
|---|---|---|---|
| Genentech | 1 | 5 | 400 % |
| EnVivo | 9 | 31 | 244 % |
| AP Pharma | 31 | 64 | 106 % |
| West-Ward Pharmaceuticals | 2 | 4 | 100 % |
| Cordis | 1 | 2 | 100 % |
| A.P. Pharma | 32 | 64 | 100 % |
| Sun Pharma | 27 | 50 | 85 % |
| Ascent Healthcare Solutions | 6 | 11 | 83 % |
| Dragon Pharmaceutical | 3 | 5 | 67 % |
| Delta Dental | 10 | 16 | 60 % |
| Company | Average | Last 24 hrs |
Increase |
|---|---|---|---|
| GenVec | 1 | 9 | 800 % |
| Daxor | 1 | 8 | 700 % |
| Delcath | 1 | 8 | 700 % |
| Cadence Pharmaceuticals | 3 | 22 | 633 % |
| Adamis Pharmaceuticals | 1 | 7 | 600 % |
| Biotest Pharmaceuticals | 2 | 13 | 550 % |
| Zimmer Dental | 1 | 6 | 500 % |
| Elixir Medical | 3 | 14 | 367 % |
| ConBio | 3 | 12 | 300 % |
| Shionogi | 1 | 4 | 300 % |